February 25, 2024

A study finds that a vaccine that destroys cancer cells in the pancreas has “promising results”.

  • BioNTech and Genentech are developing a vaccine against pancreatic cancer using messenger RNA (mRNA) technology, the same technology used in the vaccine against Covid-19.

  • The new treatment seeks to increase the patient’s immune response to the tumors.

  • Phase 1 clinical trials have been promising, according to the journal Nature.

  • Half of the participants developed T cells after treatment. T cells can recognize cancer cells and prevent them from coming back.

BioNTech logo in Marburg, Germany. Photo taken February 2, 2023 – Photo: Reuters/Fabian Beamer

The scientific journal “Nature”, one of the most respected journals in the scientific field, reported this Wednesday (10) that the results of a clinical trial on humans to develop Pancreatic cancer vaccine They had limited success and were promising.

Seeks new treatment Increase the patient’s immune response to tumors. In other words, the vaccine is A type of immunotherapy, as well as most of the immunization devices under testing. It seeks to prevent the cancer from returning, growing, or spreading.

The vaccine was developed by German research company BioNTech, together with North American Genentech, and produced based on messenger RNA (mRNA) technology – the same immunogen that BioNTech and Pfizer created to combat Covid-19.

💉 Treatment increases the body’s natural defenses against cancer cells. This is done through proteins, which are produced in the body or in a laboratory, that train a patient’s immune system to identify and destroy disease-causing cells.

📝 Phase 1 clinical trials show this Half of the study participants are 16who underwent surgery to remove a tumour, developed T cells after receiving treatment.

It could possibly be T cells It identifies cancer cells and prevents them from reappearingfor Nature.

✅ Among the eight study participants with a detectable immune response, there was no evidence of cancer recurrence 18 months after surgery, while the median time to recurrence was 13.4 months among patients who did not respond to treatment.

Despite the promising results, there is still a long way to go in the search for new therapies against cancer. In the case of this vaccine, the next step is to develop phase two and three clinical trials, before bringing the vaccine to regulatory agencies and then to the market.

“These data are very promising and will provide a framework for a planned new clinical trial,” the journal said.

Pancreatic cancer is one of the deadliest types of cancer. This is because the tumor is growing undetected. When a patient is diagnosed, the disease may be in an advanced stage, which reduces the effectiveness of treatment.

The study focused on a tumor called pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of pancreatic cancer cases. Only about 10% of patients with PDAC are alive two years after diagnosis.